Skip to content

ICAAC: Studies look at risk factors for cell changes in anus and cervix

ICAAC: Factors unrelated to HIV or side-effects of HIV treatment major cause of illness in French cohort

ICAAC: Viral load between six to 18 months predicts longer-term success of HIV therapy

ICAAC: Pilot study shows dual protease inhibitor regimen as safe and effective as traditional two class HIV therapy

ICAAC: New treatment for lipid problems shows promise in HIV patients

ICAAC: TB patients with good CD4 cell counts can safely defer HIV treatment

Improving the diagnosis of active TB in people with HIV

ICAAC: Early trials involving new GSK protease inhibitor have encouraging results

ICAAC: Nevirapine still present in breastmilk two weeks after last dose